Skip to content
Screener

Cumberland Pharmaceuticals CPIX Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$10.8M
EPS$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q2 2025

Income statement

See full
Revenue$380.8K-96.1%
Gross profit-$1.6M-120%
Operating income-$3.1M-204%
Net income-$740.7K+31.8%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$16.1M-7.2%
Total debt$5.1M-6.9%
Total equity$28.0M+6.2%
Total assets$67.9M-13.5%

Cash flow

See full
Operating cash flow$843.8K+199%
CapEx$26.5K+269%
Free cash flow$817.3K+195%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$49.37M+129%
Enterprise value$38.38M+295%
P/S1.6×+1.0×

Profitability

See full
Gross margin78.7%-3.9pp
Operating margin-17%-5.0pp
Net margin-9.3%-3.7pp

Returns & leverage

See full
Return on equity-10.8%-4.3pp
Debt / equity0.2×0.0×
Current ratio1.3×-0.1×

Segments

By product

See full
Sancuso$3.1M+42.5%
Vibativ$2.7M+10.1%
Other revenue$492.4K+130%

By geography

See full
Non-US$1.2M+81.5%

FAQ

When did Cumberland Pharmaceuticals report Q2 2025 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Cumberland Pharmaceuticals's Q2 2025 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $10.8M and eps of $0.02 for Q2 2025.
How did Cumberland Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.0% from $9.8M a year earlier and eps grew 100.0% from $0.01.
Where can I find Cumberland Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-037923) and the 10-Q periodic report (0001628280-25-039326) directly on SEC EDGAR. The filing index links above go to sec.gov.